Abbott Labs (NYSE:ABT) has never been shy about using M&A to build its business, and it was generally assumed that more deals would follow in the wake of the company's split with AbbVie (Nasdaq:ABBV). While Monday is often the preferred day to announce deals, Abbott went above and beyond this week with two acquisition announcements – both of which could be highly promising down the line.
A Better Mousetrap For The Legs?
Peripheral vascular treatment is still a high-growth market, as clinicians have an increasing array of effective tools at hand to treat blockages in the arteries of the legs – blockages that can lead to falls and amputations if not treated. Major coronary stent players like Abbott, Medtronic (NYSE:MDT), and Boston Scientific (NYSE:BSX) also develop stents for the peripheral vasculature (where they also compete with the likes of Covidien (NYSE:COV), Bard (NYSE:BCR), Johnson & Johnson (NYSE:JNJ), and Cook), but stents have long been problematic in these narrower, twisting vessels, and stents have to compete with various arthrectomy devices sold by companies including Covidien, Cardiovascular Systems (Nasdaq:CSII), and Spectranetics (Nasdaq:SPNC).
Abbott is bulking up its business here with the acquisition of IDev Technologies for $310 million. IDev has developed its SUPERA Veritas peripheral stent system, and it looks quite promising. These stents use a proprietary interwoven wire technology that attempts to mimic a more natural motion. 
So far, it looks like there's something to this technology. While peripheral stents have historically had fracture rates approaching 50% and high incidiences of restenosis (though more modern versions are much, much better), studies of the VERITAS have shown solid long-term patency and as little as zero fractures, even in what should otherwise be very difficult cases. If the data hold up, this could be a compelling peripheral platform for Abbott in a relatively short amount of time, but the stent is not yet approved for the U.S.
SEE: A Checklist For Successful Medical Technology Investment

A New Approach To A Common Procedure
Abbott has also announced the acquisition of OptiMedica, a privately-held med-tech company that has developed the Catalys Precision Laser System for cataract surgery. The Catalys uses a combination of a laser, optical coherence tomography, and pattern scanning technology to replace many of the manual steps in a cataract surgery procedure. While cataract surgery has become relatively routine, complications do tend to be associated with the various manual steps of the process, and this system could offer improvements in throughput and patient outcomes. Better still, it fills that sweet-spot in tech of “new ways of doing old things”.
Abbott will be paying $350 million upfront, with milestones worth as much as $150 million tied to sales. This acquisition should fit in well with Abbott's existing eye care business, and with the recent Valeant (NYSE:VRX) acquisition of Bausch & Lomb, this could be a good opportunity to gain share in the cataract surgery market. 
Two In, One Out
Although not packaged in with Monday's deal announcements, word has also come out that the company has ended its partnership with Stratec Biomedical. There was never all that much information on this partnership, other than that they were collaborating on some sort of automated analyzer systems for the diagnostics market. With Stratec attributing the decision to a change in Abbott's priorities, I wonder if this will lead to speculation that Abbott is deprioritizing the diagnostics business (though I'd think that's a bit of a leap at this point...).
The Bottom Line
With Abbott reporting later this week, I'll be back with a more complete discussion of valuation and Abbott's investment prospects at that time. For now, though, I would say that both of these acquisitions look like good uses of capital and both deals represent potentially transformative technologies in large and meaningful markets where Abbott already has a presence – a detail which should increase the odds of success down the line.

Related Articles
  1. Professionals

    Hard and Soft Due Diligence: What's the Difference?

    Learn about the differences between "hard" and "soft" due diligence in a mergers and acquisitions deal (M&A) and why soft diligence is increasingly important.
  2. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  3. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  4. Stock Analysis

    How UPS Plans to Benefit from Its Coyote Acquisition

    Understand the business models of UPS and Coyote Logistics. Learn about the top four ways in which UPS will benefit from the acquisition of Coyote Logistics.
  5. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  6. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  7. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  8. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  9. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  10. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. How long does it take to execute an M&A deal?

    Even the simplest merger and acquisition (M&A) deals are challenging. It takes a lot for two previously independent enterprises ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!